Editorial: Brain metastases and breast cancer subtypes

Onkologie

Volumn 33, Issue 4, 2010, Pages 143-144

  Gonzalez Angulo, Ana M ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISTANT METASTASIS; EDITORIAL; HUMAN; PROGNOSIS; BRAIN TUMOR; BREAST TUMOR; CARCINOMA; COMORBIDITY; FEMALE; METASTASIS; NOTE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; COMORBIDITY; FEMALE; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 77953787668     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296307     Document Type: Editorial

References (17)

1. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumors. Nature 2000:406: 747-752.
2. Sorlie T: Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004;40:2667-2675.
3. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
4. Brenton JD, Carey LA, Ahmed AA, et al.: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005;23:7350-7360.
5. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 2004;1;22:3608-3617.
6. Tsukada Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-2354.
7. Patanaphan V, Salazar OM, Risco R: Breast cancer: metastatic patterns and their prognosis. Southern Medical Journal 1988;81:1109-1112.
8. DiStefano A, Yap HY, Hortobagyi GN, et al.: The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-1918.
9. Engel J, EcKel R, Aydemir U, et al.: Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1186-1195.
10. Pestalozzi BC, Zahrieh D, Price KN, et al.: Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-944.
11. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, et al.: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK 5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-1104.
12. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704.
13. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15,219-225.
14. Samaan NA, Buzdar AU, Aldinger KA et al.: Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981;47:554-560.
15. Kown HC, Oh SY, Kim SH, et al.: Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 2010;33: DOI: 10.1159/ 000286281.
16. Dawood S, Broglio K, Esteva FJ, et al.: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20: 621-627.
17. Dawood S, Broglio K, Esteva FJ, et al.: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19: 1242-1248.